This inventor holds 1 USPTO granted patent. Top assignee: Beijing University of Agriculture. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Innovations of Haiwen Hu in Cancer Treatment
Introduction
Haiwen Hu is a notable inventor based in Beijing, China. He has made significant contributions to the field of chemical and pharmaceutical technology. His work primarily focuses on developing inhibitors for critical signaling pathways involved in cancer progression.
Latest Patents
Haiwen Hu holds a patent for a "STAT3 and ERK signal pathway inhibitor comprising mogrosides and analogs thereof." This invention relates to a chemical and pharmaceutical technology aimed at inhibiting the phosphorylation of the transcription factor STAT3 and the ERK pathway. The inhibitor consists mainly of mogrosides and/or their analogs, which have shown effectiveness in inhibiting cancer cell proliferation and promoting apoptosis. The preparation method for these compounds is characterized by its simplicity, strong operability, and high purity of products. This innovation has promising applications in the development of drugs for treating tumors.
Career Highlights
Haiwen Hu is affiliated with the Beijing University of Agriculture, where he continues to advance his research in cancer treatment. His work has garnered attention for its potential impact on therapeutic strategies against various cancers.
Collaborations
Some of his notable coworkers include Can Liu and Dequan Dou, who have contributed to his research endeavors.
Conclusion
Haiwen Hu's innovative work in developing STAT3 and ERK signal pathway inhibitors represents a significant advancement in cancer treatment. His contributions to pharmaceutical technology hold promise for improving therapeutic outcomes for cancer patients.